Edmundo Muniz, M.D., Ph.D.
President and Chief Executive Officer

Dr. Muniz brings over 22 years of drug development experience in oncology, Cardiovascular, and infectious disease. Prior to joining Tigris, Dr. Muniz was Vice President for Lilly Research Laboratories Global Oncology Platform at Eli Lilly and Company. At Lilly, Dr. Muniz was responsible for Phase II, III and IV clinical trials for oncology compounds worldwide and for Global Marketing Pre-launch.

Under Dr. Muniz's leadership, Lilly Oncology achieved 9 major oncology submissions worldwide, with all 9 of those already having gained approval in the US, Europe and Japan. Such projects include Dr. Muniz's extensive involvement in the development of approved oncology therapeutics Alimta® and Gemzar®. Additionally, Dr. Muniz led the launch of Lilly Oncology on Canvas: Expressions of a Woman's Cancer Journey, an international art exhibition that displays works from over 400 cancer survivors, family members, care providers and friends. Prior to joining Eli Lilly, Dr. Muniz completed a PhD in Epidemiology and International Health at the University of Michigan and later completed a residency in Preventive Medicine and a Fellowship in Epidemic Intelligence with the Centers for Disease Control and Prevention (CDC) in Atlanta.

Alexander Mironov
Vice President of Operations

Mr. Mironov has over 10 years of drug development, regulatory and operations experience. He joined Tigris in January 2011 in the capacity of VP of Operations. Prior to Tigris, Alexander was with a number of start-up specialty pharmaceutical companies backed by leading venture capital firms like NEA, Domain Associates, MPM, Apax Partners, Quaker BioVentures, NewSpring Capital and Sanders Morris Harris. Most recently as acting VP of Project and Regulatory Management at NexGenix Pharmaceuticals, Alexander oversaw the company’s regulatory affairs and program management activities leading to the company’s oncology IND for its Hsp90 inhibitor platform. As a Sr. Director at EKR Therapeutics, Mr. Mironov established the regulatory affairs department; integrated processes as well led FDA approvals of key sNDAs. Prior to EKR, Alexander was an Associate Director of Regulatory Affairs with Esprit Pharma which was acquired by Allergan for $370MM. Prior to Esprit, with Valera Pharmaceuticals, Mr. Mironov managed FDA interactions and submissions of multiple INDs (Phase 1, 2, 3) and NDAs. Earlier in his career, Alex was affiliated with Pfizer, Inc., Ranbaxy Pharmaceuticals, and interned with Novartis AG and Schering-Plough. Mr. Mironov has a B.S. in Biochemistry from Rutgers University and has attended executive management training at Kellogg Business School, Northwestern University.

Joseph V. Pergolizzi, Jr., M.D.
Chief Medical Officer

Joseph V. Pergolizzi, Jr., MD, joined Tigris Pharmaceuticals in 2010 as Chief Medical Advisor. Dr. Pergolizzi is an internationally recognized thought leader in pain medicine, anesthesia, internal medicine, clinical research, and drug discovery. Dr. Pergolizzi is the author of over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise. He serves as Editor-in-Chief of The Clinical Researcher and is an editorial board member/reviewer for many scientific journals including JAMA, Lancet, Pain Practice, Experimental Medicine, Pain Medicine, and the American Journal of Managed Care.

Dr. Pergolizzi is Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine; an Adjunct Faculty member in the Department of Anesthesiology at Georgetown University School of Medicine in Washington; and co-founder and chairman of the board of the Association of Chronic Pain Patients. Dr. is the co-founder and Chief Operating Officer, of NEMA Research, a full service contract research implementation organization. Prior to joining NEMA, Dr. Pergolizzi was the Director of Business Development and Financial Affairs for the Johns Hopkins University School of Medicine’s Clinical Trials Unit. In this capacity, he established Master Clinical Trial Agreements between Johns Hopkins University and various pharmaceutical companies.

Dr. Pergolizzi earned his MD with highest honors from Ross University School of Medicine. He completed his residency in anesthesia at Georgetown University School of Medicine and a clinical research fellowship in the Department of Medicine at Johns Hopkins University School of Medicine. As an anesthesiologist, he held positions on various institutional executive committees including the Pharmacy and Therapeutics committee as well as its sub- committee on Medical Errors. Dr. Pergolizzi was a member of the SmithKline Beecham Partners in Development Program and holds various advisory, board, and consulting positions on many CRO’s, medical device manufacturers, and pharmaceutical companies. As an internationally recognized key opinion leader in pain management, he serves on numerous boards and committees around the world and is a steering committee member of the Food and Drug Administration’s Safe Use Initiative.